Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer	Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 2	2026-04-09		NCT04841148

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Abramson Cancer Center at Penn Medicine	137
Breast Cancer Research Foundation	40
Johns Hopkins University	579
Pfizer	431
Translational Breast Cancer Research Consortium	19

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana-Farber Cancer Institute	Boston	United States	626
Georgetown University	Washington D.C.	United States	38
Indiana University	Indianapolis	United States	160
University of Chicago	Chicago	United States	312
University of Pennsylvania	Philadelphia	United States	507
University of Washington	Seattle	United States	172
Vanderbilt University	Nashville	United States	51